Abstract
PEDF is a highly effective endogenous inhibitor of angiogenesis. However, the pathophysiological role of PEDF in therapeutic angiogenesis in the setting of limb ischemia is not fully understood. In this study, we investigated whether inhibition of PEDF could augment vascular endothelial growth factor (VEGF)-induced therapeutic angiogenesis and blood flow recovery in ischemic hindlimbs of precocious-aging klotho mice. Adductor PEDF mRNA levels in nontreated mice were dramatically decreased at day 3 and 7 after ischemic surgery, whereas those in VEGF-treated mice were significantly increased after the surgery. VEGF treatment caused a progressive improvement of limb perfusion after induction of ischemia, which was augmented by the simultaneous treatment with anti-PEDF Ab. Further, PEDF administration was found to significantly impair the recovery of limb perfusion and post-ischemic angiogenesis in VEGF-treated mice. However, anti-PEDF Ab administration did not enhance the VEGF-induced increase in capillary number in ischemic adductor muscles. Our present study suggests that blockade of PEDF is a novel therapeutic strategy for limb ischemia, which could potentiate the beneficial effects of VEGF on therapeutic angiogenesis.
Keywords: PEDF, Post-ischemic angiogenesis, VEGF, PAD
Letters in Drug Design & Discovery
Title: Inhibition of Pigment Epithelium-Derived Factor (PEDF) Augments Vascular Endothelial Growth Factor (VEGF)-Induced Recovery of Limb Perfusion after Ischemia in Klotho Mouse
Volume: 7 Issue: 7
Author(s): Ken Arima, Sho-ichi Yamagishi, Takanori Matsui, Yutaka Saito, Yoshio Katsuki, Ken-ichiro Sasaki, Yousuke Katsuda, Hisashi Kai and Tsutomu Imaizumi
Affiliation:
Keywords: PEDF, Post-ischemic angiogenesis, VEGF, PAD
Abstract: PEDF is a highly effective endogenous inhibitor of angiogenesis. However, the pathophysiological role of PEDF in therapeutic angiogenesis in the setting of limb ischemia is not fully understood. In this study, we investigated whether inhibition of PEDF could augment vascular endothelial growth factor (VEGF)-induced therapeutic angiogenesis and blood flow recovery in ischemic hindlimbs of precocious-aging klotho mice. Adductor PEDF mRNA levels in nontreated mice were dramatically decreased at day 3 and 7 after ischemic surgery, whereas those in VEGF-treated mice were significantly increased after the surgery. VEGF treatment caused a progressive improvement of limb perfusion after induction of ischemia, which was augmented by the simultaneous treatment with anti-PEDF Ab. Further, PEDF administration was found to significantly impair the recovery of limb perfusion and post-ischemic angiogenesis in VEGF-treated mice. However, anti-PEDF Ab administration did not enhance the VEGF-induced increase in capillary number in ischemic adductor muscles. Our present study suggests that blockade of PEDF is a novel therapeutic strategy for limb ischemia, which could potentiate the beneficial effects of VEGF on therapeutic angiogenesis.
Export Options
About this article
Cite this article as:
Arima Ken, Yamagishi Sho-ichi, Matsui Takanori, Saito Yutaka, Katsuki Yoshio, Sasaki Ken-ichiro, Katsuda Yousuke, Kai Hisashi and Imaizumi Tsutomu, Inhibition of Pigment Epithelium-Derived Factor (PEDF) Augments Vascular Endothelial Growth Factor (VEGF)-Induced Recovery of Limb Perfusion after Ischemia in Klotho Mouse, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526313
DOI https://dx.doi.org/10.2174/157018010791526313 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of the Possible Mechanisms of Action of Tocotrienol – A Potential Antiosteoporotic Agent
Current Drug Targets Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Metallic Nanoparticles as SERS Agents for Biomolecular Imaging
Current Pharmaceutical Biotechnology Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Cellular Systems Biology Profiling Applied to Cellular Models of Disease
Combinatorial Chemistry & High Throughput Screening Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Involvement of Adipogenic Potential of Human Bone Marrow Mesenchymal Stem Cells (MSCs) in Osteoporosis
Current Stem Cell Research & Therapy Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells
Mini-Reviews in Medicinal Chemistry Trans-Platinum Complexes with Promising Antitumor Properties
Medicinal Chemistry Reviews - Online (Discontinued) Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Cartilage Regeneration Using Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy